RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
1-Year Return
12.81%
This Quarter Return
-8.99%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$798M
AUM Growth
-$110M
(-12%)
Cap. Flow
-$2.7M
Cap. Flow
% of AUM
-0.34%
Top 10 Holdings %
Top 10 Hldgs %
29.72%
Holding
97
New
9
Increased
24
Reduced
42
Closed
4
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$27.9M |
| 2 |
Merck
MRK
|
$18.1M |
| 3 |
AbbVie
ABBV
|
$12.9M |
| 4 |
Esperion Therapeutics
ESPR
|
$8.94M |
| 5 |
Nektar Therapeutics
NKTR
|
$8.65M |
Top Sells
| 1 |
Horizon Bancorp
HBNC
|
$26.2M |
| 2 |
Humana
HUM
|
$11.5M |
| 3 |
Incyte
INCY
|
$8.5M |
| 4 |
HCA Healthcare
HCA
|
$7.37M |
| 5 |
Elevance Health
ELV
|
$7.2M |
Sector Composition
| 1 | Healthcare | 92.7% |
| 2 | Industrials | 0.42% |
| 3 | Technology | 0.13% |
| 4 | Financials | 0.1% |
| 5 | Energy | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RARX
51
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $5.77M | 0.72% |
244,000
+15,000
| +7% | +$355K |
|
52
Exelixis
EXEL
$10.1B
| $5.66M | 0.71% |
320,000
-140,000
| -30% | -$2.48M |
|
53
Alnylam Pharmaceuticals
ALNY
$59.4B
| $5.55M | 0.7% |
69,000
-12,550
| -15% | -$1.01M |
|
|
STML
54
DELISTED
Stemline Therapeutics, Inc.
STML
| $5.32M | 0.67% |
511,023
+17,024
| +3% | +$177K |
|
|
DPLO
55
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $5.19M | 0.65% |
1,060,000
-143,405
| -12% | -$703K |
|
|
BLUE
56
DELISTED
bluebird bio
BLUE
| $4.78M | 0.6% |
4,014
-1,390
| -26% | -$1.65M |
|
|
EPZM
57
DELISTED
Epizyme, Inc
EPZM
| $4.64M | 0.58% |
450,028
-43,651
| -9% | -$450K |
|
58
Dynavax Technologies
DVAX
$1.17B
| $4.41M | 0.55% |
1,234,335
| – | – |
|
59
Alkermes
ALKS
$4.77B
| $4.29M | 0.54% |
220,000
+99,601
| +83% | +$1.94M |
|
|
SILK
60
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $4.07M | 0.51% |
+125,000
| New | +$4.07M |
|
|
RDUS
61
DELISTED
Radius Health, Inc.
RDUS
| $3.86M | 0.48% |
+150,000
| New | +$3.86M |
|
62
Rigel Pharmaceuticals
RIGL
$720M
| $3.74M | 0.47% |
200,000
-26,494
| -12% | -$495K |
|
|
DERM
63
DELISTED
Dermira, Inc.
DERM
| $3.51M | 0.44% |
549,300
+48,971
| +10% | +$313K |
|
|
HMSY
64
DELISTED
HMS Holdings Corp.
HMSY
| $3.39M | 0.42% |
98,300
-1,700
| -2% | -$58.6K |
|
|
ICPT
65
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $3.16M | 0.4% |
47,600
+10,000
| +27% | +$664K |
|
|
AIMT
66
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $3.12M | 0.39% |
149,201
| – | – |
|
|
NSTG
67
DELISTED
NanoString Technologies, Inc.
NSTG
| $3.07M | 0.38% |
142,126
+22,126
| +18% | +$478K |
|
|
SAGE
68
DELISTED
Sage Therapeutics
SAGE
| $2.81M | 0.35% |
20,000
-1,639
| -8% | -$230K |
|
|
XLRN
69
DELISTED
Acceleron Pharma Inc.
XLRN
| $2.77M | 0.35% |
70,000
| – | – |
|
70
Madrigal Pharmaceuticals
MDGL
$9.61B
| $2.59M | 0.32% |
30,000
-7,225
| -19% | -$623K |
|
|
RVNC
71
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.26M | 0.28% |
173,917
-19,264
| -10% | -$250K |
|
72
Abeona Therapeutics
ABEO
$352M
| $2.26M | 0.28% |
40,000
+14,035
| +54% | +$793K |
|
73
Guardant Health
GH
$7.65B
| $2.23M | 0.28% |
+35,000
| New | +$2.23M |
|
|
VRAY
74
DELISTED
ViewRay, Inc.
VRAY
| $1.84M | 0.23% |
635,434
-28,589
| -4% | -$82.9K |
|
|
ARQL
75
DELISTED
Arqule Inc
ARQL
| $1.43M | 0.18% |
+200,000
| New | +$1.43M |
|